SCHEMBL188170

SCHEMBL188170

CC(C)C(=O)N1CCNCC1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CA2 P00918 2/20 0.48
CA12 O43570 1/20 0.48
CA1 P00915 1/20 0.48
CA9 Q16790 1/20 0.48
CHRNB2 P17787 2/20 0.47
CHRNA3 P32297 2/20 0.47
CHRNA4 P43681 2/20 0.47
CHRNB3 Q05901 2/20 0.47
CHRNA6 Q15825 2/20 0.47
CHKA P35790 1/20 0.46
CHRM5 P08912 1/20 0.41
CHRM3 P20309 1/20 0.41
HPGD P15428 1/20 0.41
SIGMAR1 Q99720 1/20 0.39
HSD11B1 P28845 1/20 0.38
CYP1A2 P05177 1/20 0.38
MEN1 O00255 1/20 0.36
ALDH1A1 P00352 1/20 0.36
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4365547 1.00 CA2 (0.48) CA2CA12CA1CA9CHRNB2
Hydrochloric Acid SCHEMBL2047725 0.98 CA2 (0.46) CA2CA12CA1CA9CHRNB2
SCHEMBL10157078 0.92 CA2 (0.50) CA2CA12CA1CA9CHRNB2
Trifluoroacetic Acid SCHEMBL29701101 0.87 PKM (0.46) CA2CA12CA1CA9CHRNB2
Trifluoroacetic Acid SCHEMBL29701100 0.87 PKM (0.46) CA2CA12CA1CA9CHRNB2
SCHEMBL10615755 0.86 CHRNB2 (0.48) CA2CA12CA1CA9CHRNB2
SCHEMBL28015832 0.85 CA2 (0.43) CA2CA12CA1CA9CHRNB2
SCHEMBL2910273 0.84 CA2 (0.46) CA2CA12CA1CA9CHRNB2
SCHEMBL5440196 0.84 CA2 (0.46) CA2CA12CA1CA9CHRNB2
SCHEMBL2910275 0.84 CA2 (0.46) CA2CA12CA1CA9CHRNB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 506 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104046246-B The chemical-mechanical planarization of tungsten-containing substrate 气体产品与化学公司 2016-06-15 CN claimed
US-20140273458-A1 Chemical Mechanical Planarization for Tungsten-Containing Substrates AIR PRODUCTS AND CHEMICALS, INC. (US) 2014-09-18 US claimed
EP-2779217-A2 Chemical mechanical planarization for tungsten-containing substrates AIR PRODUCTS AND CHEMICALS, INC. (US) 2014-09-17 EP claimed
CN-104046246-A Chemical Mechanical Planarization for Tungsten-Containing Substrates AIR PROD & CHEM 2014-09-17 CN claimed
US-20260132111-A1 Host-Targeted Pan-Respiratory Antiviral Small Molecule Therapeutics PROSETTA BIOSCIENCES INC (US) 2026-05-14 US disclosed
US-20250388584-A1 TPK AGONIST AND METHOD FOR TREATING NEURODEGENERATIVE DISEASES USING SAME SHANGHAI RAISING PHARMACEUTICAL CO LTD (CN) 2025-12-25 US disclosed
US-20250388589-A1 TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF DANATLAS PHARMACEUTICALS CO LTD (CN) 2025-12-25 US disclosed
US-20250346564-A1 INHIBITORS OF PARG ARASE THERAPEUTICS INC (US) 2025-11-13 US disclosed
US-12459901-B2 Host-targeted pan-respiratory antiviral small molecule therapeutics PROSETTA BIOSCIENCES, INC. (US) 2025-11-04 US disclosed
US-12454547-B2 Steroidal compositions and methods of treating lipogenic cancers Asteroid Therapeutics (US) 2025-10-28 US disclosed
WO-2025215110-A1 NEW AMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS SOS1 INHIBITORS LES LABORATOIRES SERVIER (FR) 2025-10-16 WO disclosed
EP-4556007-A1 TPK AGONIST AND METHOD FOR TREATING NEURODEGENERATIVE DISEASES USING SAME Shanghai Raising Pharmaceutical Co., Ltd. (CN) 2025-05-21 EP disclosed
US-5780470-A TREATING SLEEP DISORDERS AND DEPRESSION BRISTOL-MYERS SQUIBB COMPANY (US) 1998-07-14 US disclosed
US-5756505-A N-acylpiperazine derivative, antibacterial drug and anti-ulcer drug SHISEIDO CO., LTD. (JP) 1998-05-26 US disclosed
EP-0745597-A2 Novel melatonergic indanyl piperazines or homopiperazines BRISTOL-MYERS SQUIBB COMPANY (US) 1996-12-04 EP disclosed
EP-0735031-A1 N-acetylpiperazine derivative, antibacterial drug, and anti-ulcer drug SHISEIDO COMPANY LIMITED (JP) 1996-10-02 EP disclosed
US-4328223-A 2-Amino-3a,4,5,6-tetrahydro-perimidine derivatives and their medicinal use in combatting circulatory diseases BAYER AKTIENGESELLSCHAFT (DE) 1982-05-04 US disclosed
EP-0049683-A2 Imidazo-rifamycines, process for their preparation, pharmaceutical preparations containing them and their use CIBA-GEIGY AG (CH) 1982-04-14 EP disclosed
EP-0004904-B1 2-AMINO-3A,4,5,6-TETRAHYDROPERIMIDINE DERIVATIVES, MEDICAMENTS CONTAINING THEM AND PROCESS FOR THEIR PREPARATION BAYER AG (DE) 1981-07-29 EP disclosed
EP-0004904-A1 2-Amino-3a,4,5,6-tetrahydroperimidine derivatives, medicaments containing them and process for their preparation BAYER AG (DE) 1979-10-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12454547-B2 Steroidal compositions and methods of treating lipogenic cancers SREBF1, SREBF2, NR1H3 CA2 4355/4885CA12 4344/4885CA1 4426/4885
US-20260132111-A1 Host-Targeted Pan-Respiratory Antiviral Small Molecule Therapeutics NCOR1, HAVCR2, NR3C1 CA2 1795/4885CA12 975/4885CA1 2888/4885
US-20250346564-A1 INHIBITORS OF PARG PARG, PARN, PLG CA2 836/4885CA12 2361/4885CA1 2609/4885
US-12459901-B2 Host-targeted pan-respiratory antiviral small molecule therapeutics MAVS, SARS1, ZC3HAV1 CA2 2749/4885CA12 1676/4885CA1 4374/4885
US-20250388589-A1 TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF CYP4A11, CYP11B1, CYP2D6 CA2 445/4885CA12 396/4885CA1 863/4885
US-20250388584-A1 TPK AGONIST AND METHOD FOR TREATING NEURODEGENERATIVE DISEASES USING SAME PDXK, SLC19A2, NADK CA2 2807/4885CA12 4650/4885CA1 3031/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.